Holen Sie sich die Stockscreener-App
0.1138
5.25%
-0.0063
Vorhandelsmarkt:
.12
0.0062
+5.45%
Liminatus Pharma Inc Aktie (LIMN) Neueste Nachrichten
Liminatus Pharma (LIMN) Faces Selling Pressure, Testing Key Support at $0.11Money Flow - newsline.com
Liminatus Pharma Warrants (LIMNW) Holds at $0.08 as Trading StallsPut Flow Alert - newsline.com
Liminatus Pharma (LIMN) Extends Decline, Testing Key Support at $0.11OBV Breakout - newsline.com
LIMN Should I Buy - Intellectia AI
Liminatus Pharma Warrants (LIMNW) Hold Steady Near Key Support LevelVolume Oscillator - newsline.com
Liminatus Pharma (LIMN) Slips 5.77% as Selling Pressure Persists Below $0.14 ResistanceJelly Roll Trade - newsline.com
Liminatus Pharma Inc. (LIMN) Slides 5.95% as Stock Tests Key Support at $0.13Regression Channel - newsline.com
Liminatus Pharma secures $1.9M cash via warrant exercises - MSN
Liminatus Pharma Secures Liquidity Through Warrant Inducement Deal - TipRanks
[8-K] Liminatus Pharma, Inc. Reports Material Event - Stock Titan
Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds - The Manila Times
Liminatus Pharma (NASDAQ: LIMN) cuts warrant exercise price; 13.8M warrants tied to 20.7M shares - Stock Titan
Liminatus Pharma (LIMN) Slides 8.89%: Testing Key $0.15 Support LevelVolatility Stop - newsline.com
Liminatus Pharma (LIMN) Slips 6% as Stock Tests Key Support at $0.16Order Block - newsline.com
LIMINATUS PHARMA, INC. Files Form 8-K for NASDAQ Listing – Company Information and SEC Filing Details - Minichart
Liminatus Pharma (LIMN) Holds Steady Near Resistance – Consolidation Phase May Precede Directional MoveSentiment Extreme - newsline.com
Liminatus Pharma Appeals Nasdaq Delisting, Listing Temporarily Intact - TipRanks
Liminatus Pharma Received Notice of Delisting - TradingView
Liminatus Pharma (LIMN) appeals Nasdaq delisting after market value shortfall - Stock Titan
Liminatus Pharma Inc. (LIMN) Surges Over 12% as Bullish Momentum BuildsBPI Reversal - The Legal Advocate
Liminatus Pharma - The Pharma Letter
Liminatus Pharma (LIMN) Shares Slide 3.25% as Selling Pressure Mounts Near SupportRetail Volume - newsline.com
Liminatus Pharma(LIMN) Stock Options Chain | Quotes & News - Moomoo
Liminatus announces proposed merger with InnocsAI - The Pharma Letter
Liminatus Pharma notifies NASDAQ of impending delisting; plans to appeal - MSN
Liminatus Pharma is trending overnight — here's why LIMN stock surged over 79% in after-hours session - MSN
Liminatus Pharma (LIMN) Faces Delisting from Nasdaq - GuruFocus
Liminatus Pharma (LIMN) Faces Nasdaq Delisting Notice Amid Compl - GuruFocus
Liminatus Pharma (LIMN) Plunges 31% as Support Level Approaches – Key Levels to WatchExpert Breakout Alerts - Newser
Liminatus Pharma receives Nasdaq delisting notice - TipRanks
Number of shareholders of Liminatus Pharma, Inc. – NASDAQ:LIMN - TradingView
LIMN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Unusual volume stocks in Friday's session - ChartMill
Liminatus Pharma (LIMN) Stock: Surges Ahead of Nasdaq Delisting Deadline - MEXC
Liminatus Pharma (LIMN) Stock: Nasdaq Delisting Warning Sparks Volatile Trading Session - Blockonomi
Liminatus Pharma (LIMN) Stock Jumps 31% Despite Looming Nasdaq Delisting Threat - MoneyCheck
Liminatus Pharma faces Nasdaq delisting after compliance failure - Investing.com India
Liminatus Pharma faces Nasdaq delisting after compliance failure By Investing.com - Investing.com Australia
Liminatus Pharma to be delisted from Nasdaq for failing market value rules, plans to appeal. - Pluang
Liminatus Pharma Announces Nasdaq Delisting Notification - lincolnjournal.com
Liminatus Pharma, Inc. Receives Nasdaq Delisting Notice Following Non-Compliance With Market Value Requirements - Moomoo
Liminatus Pharma, Inc. Receives Nasdaq Delisting Notice Following Non-Compliance with Market Value Requirements - Quiver Quantitative
Liminatus Pharma faces Nasdaq delisting after market value shortfall - Stock Titan
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):